Telehealth 'Pill Mills' Are Turning Easy Access Into a Patient-Safety Problem

How Direct-to-Consumer Prescription Sites Moved From Convenience to Low-Oversight Channel

A Columbus, Ohio, geriatrician spent weeks trying to stabilize an older patient whose blood pressure kept dropping. The missing variable was not in the patient's chart: he had quietly ordered an erectile-dysfunction medication through a direct-to-consumer telehealth website and was too embarrassed to tell his regular doctor. Chad Wittekind says the case is part of a pattern, including a patient who received ketamine tablets online and another who was prescribed a GLP-1 weight-loss drug despite a body mass index of 18.7—below the level that should have disqualified them under FDA guidance.

The sites generally begin with a social-media ad, take credit cards rather than insurance, and replace a video visit with a short asynchronous questionnaire. A clinician the patient never meets reviews the form, sometimes within minutes, writes a prescription—often recurring—and routes it to a pharmacy that mails the drug. The model filled a real gap: doctor appointments can take weeks, insurance approval is burdensome, and telehealth expanded rapidly during pandemic-era relaxations that later became permanent.

The business has grown quickly. Entrepreneurs can launch a niche telehealth brand without being physicians; outside firms connect them with clinician networks and pharmacies, and infrastructure providers such as CareValidate report 20% month-over-month growth. Elliot Tabibian, now 22, started with medical-marijuana telemedicine as a teenager and now runs sites including one for medical car-window-tint exemptions. Grand View Research estimates the U.S. telehealth market at $28.3 billion in 2025, rising to $60.4 billion by 2033.

The patient-safety evidence is now catching up. A July 2026 JAMA study that attempted to obtain prescriptions from 49 telehealth sites documented limited clinician engagement and prescriptions issued in as little as five minutes. A Senate investigation found that 85–100% of patients who interacted with a provider at certain sites received prescriptions. Lawsuits allege harm from prescribed ketamine, Adderall and hair-loss drugs, and some families say patients died after inadequate telehealth care.

What the Columbus Cases, JAMA Study and Cash-Pay Economics Reveal

The telehealth story is not simply good access versus bad actors. The clinical damage often appears later, in someone else's exam room, because the prescribing system is disconnected from a patient's regular care.

Columbus Cases Show the Hidden Cost of Fragmented Prescribing

Wittekind's blood-pressure case was ultimately solved only after repeated questions revealed the online erectile-dysfunction prescription. That points to a concrete risk: a cash-pay telehealth form cannot perform reconciliation with a patient's other medications. The GLP-1 prescription to a patient with a BMI of 18.7 is another example of screening failing against established clinical guidance, not just a paperwork lapse.

Cash-Pay Incentives Reward Volume, Not Follow-Up

Researcher Reshma Ramachandran says some doctors working for these sites face prescription quotas or bonuses tied to volume. Infrastructures like CareValidate, and investors backing low-overhead startups, benefit when more consultations convert to recurring prescriptions. When a Senate probe found that 85–100% of patient interactions ended in a script, the pattern suggests screening is functioning as a sales funnel rather than a clinical gate. That is an interpretation, but it is consistent with the JAMA finding that some patients received prescriptions without uploading required photos or meeting site rules.

The JAMA Study Turns Individual Complaints Into a Systemic Finding

Researchers looked across 49 websites and found the same clinician could issue multiple prescriptions for the same patient across sites, with little real engagement. The authors concluded the motivation was to prescribe rather than to communicate risk. Because the study is recent and peer-reviewed, it strengthens the case that poor practice is not limited to a few outliers.

Regulation and Ethics Are Running Behind the Gold Rush

Experts including Arthur Caplan, Erin Fuse Brown and Anjali Deshmukh argue that the model has outpaced oversight. Many sites claim to be mere platforms, which helps them avoid traditional provider accountability. The upcoming FDA decision on specialty pharmacy dispensing of six peptides could expand demand through these channels, even though few peptides have strong clinical proof outside GLP-1s. The most realistic near-term consequence is more enforcement and litigation before any uniform federal rules emerge, because current oversight is fragmented across state and federal lines.

Checks for Patients and Providers Before an Online Prescription Becomes a Risk

For patients and clinicians, the precautions below follow from the failures documented in the article.

For patients considering a direct-to-consumer prescription

• Before using a cash-pay site for a GLP-1, confirm you meet medical eligibility; the article records a prescription issued at a BMI of 18.7, below FDA guidance.
• Ask whether the product is a compounded version and whether that status is clearly disclosed; the JAMA study found some sites sold compounded GLP-1s without clear disclosure.
• Tell your regular clinician about any online prescription right away, especially before adding or adjusting other drugs, because the Columbus blood-pressure case was solved only after that disclosure.
• Find out in advance how to contact the prescribing clinician for side effects; Wittekind says follow-up is often unavailable and problems return to the primary care provider.
• Verify the prescriber's state license and whether a live video or phone evaluation is required; the JAMA study found prescriptions issued in as little as five minutes with limited engagement.

For clinicians

• Ask patients directly about online, cash-pay and medically sensitive medications during medication reconciliation, since they may be withheld out of embarrassment.
• When seeing unexplained cardiac, psychiatric or weight-related symptoms, screen for telehealth-obtained ketamine, GLP-1s and erectile-dysfunction drugs—the categories Wittekind and the lawsuits identify.